| dbo:abstract |
TopoTarget (Nasdaq Copenhagen: TOPO) was a Copenhagen-based biotechnology company focused on the discovery and development of drugs and therapies to treat cancer. In 2014, it merged with BioAlliance Pharma and is now part of . It was founded in 2000 by a group of clinicians. TopoTarget was involved in collaborations with both academia and industry. In 2001 they began collaborating with the National Cancer Institute, a component of the US National Institutes of Health. Since their acquisition of , they have been collaborating with the Netherlands Cancer Institute. They also collaborate with Rigshospitalet, the national hospital of Denmark. TopoTarget has also collaborated with other companies, including Novartis since 2003, and Lundbeck as of October 2007; Topotarget has been member of the Danish Innovation Network Biopeople since 2005. (en) |
| dbo:assets |
5.8541E8 |
| dbo:equity |
4.1179E8 |
| dbo:foundingYear |
2000-01-01 (xsd:gYear) |
| dbo:industry |
dbr:Biotechnology |
| dbo:keyPerson |
dbr:Chief_Executive_Officer dbr:CFO dbr:Chairman_of_the_Board |
| dbo:location |
dbr:Denmark dbr:Copenhagen |
| dbo:netIncome |
1.4046E8 |
| dbo:numberOfEmployees |
53 (xsd:nonNegativeInteger) 68 (xsd:nonNegativeInteger) |
| dbo:operatingIncome |
1.3249E8 |
| dbo:revenue |
4.3979E7 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/TopoTarget_logo.jpg?width=300 |
| dbo:type |
dbr:Public_company |
| dbo:wikiPageExternalLink |
http://www.topotarget.com/ http://molpharm.aspetjournals.org/cgi/content/full/70/5/1503 http://www.bio-medicine.org/biology-technology-1/TopoTarget-Successfully-Buys-Back-Full-Control-of-Belinostat-4752-3/ http://www.topotarget.com http://findarticles.com/p/articles/mi_m0HXI/is_2006_Nov_15/ai_n24995868/ https://web.archive.org/web/20090705010929/http:/www.bio-medicine.org/biology-technology-1/TopoTarget-Successfully-Buys-Back-Full-Control-of-Belinostat-4752-3/ https://web.archive.org/web/20090705035811/http:/findarticles.com/p/articles/mi_m0HXI/is_2006_Nov_15/ai_n24995868/ https://web.archive.org/web/20170515221749/http:/www.biochemj.org/bj/409/bj4090581.htm https://www.webcitation.org/5h2WGkzc0%3Furl=http:/molpharm.aspetjournals.org/cgi/content/full/70/5/1503 http://www.medicalnewstoday.com/articles/120656.php http://www.biochemj.org/bj/409/bj4090581.htm |
| dbo:wikiPageID |
20579288 (xsd:integer) |
| dbo:wikiPageLength |
29390 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1094222004 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Cancer dbr:Carboplatin dbr:Psoriasis dbr:FDA_Fast_Track_Development_Program dbr:New_Drug_Application dbr:HSP90 dbr:Topoisomerase_II dbc:Cancer_research dbr:Breast_cancer dbr:Denmark dbr:Rigshospitalet dbr:United_Kingdom dbr:United_States dbc:2014_disestablishments_in_Denmark dbr:Investor_relations dbr:John_Wiley_&_Sons dbr:Public_company dbr:LEO_Pharma dbr:Copenhagen dbr:Melanoma dbr:OMX dbr:Orphan_drug dbr:Small_molecule dbr:Germany dbr:Antibody dbr:Apoptosis dbr:Leukemia dbr:Ligand dbr:Lundbeck dbr:Lung_cancer dbr:Lymphoma dbr:Malaria dbr:Mammalian_target_of_rapamycin dbr:Siramesine dbr:Dentition dbr:Clinical_trials dbr:Basal_cell_carcinoma dbr:Subcutaneous_tissue dbr:Marketing dbr:Medicon_Valley_Alliance dbr:CBS_Interactive dbr:CEO dbr:Actinic_keratosis dbr:Tumor dbr:Tumorigenesis dbr:Doctor_of_Medicine dbc:Biotechnology_companies_disestablished_in_2014 dbr:HER2 dbr:Pericyte dbr:American_Society_for_Pharmacology_and_Experimental_Therapeutics dbc:Biotechnology_companies_established_in_2000 dbr:Cutaneous_T-cell_lymphoma dbr:Danish_krone dbr:Drug_development dbr:Europe dbr:European_Commission dbr:Familial_adenomatous_polyposis dbr:Nicotinamide_adenine_dinucleotide dbr:Novartis dbr:Paclitaxel dbr:Cell_proliferation dbr:Fas_receptor dbr:Histone_deacetylase_inhibitor dbr:Recombinant_protein dbr:Hematological dbr:Histone_deacetylase dbr:EDA_(gene) dbr:Atopic_dermatitis dbr:APMIS dbc:Biotechnology_companies_of_Denmark dbc:Companies_listed_on_Nasdaq_Copenhagen dbc:Danish_companies_established_in_2000 dbr:Acne dbr:Chemotherapy dbr:Chief_Executive_Officer dbr:Biochemical_Journal dbr:Biopeople dbr:Biotechnology dbr:Sweat dbr:Switzerland dbr:Dexrazoxane dbr:Assay dbc:Defunct_companies_based_in_Copenhagen dbr:PhD dbr:Metastases dbr:National_Cancer_Institute dbr:National_Institutes_of_Health dbr:Netherlands_Cancer_Institute dbr:CFO dbr:CNS_disorders dbr:Chairman_of_the_Board dbr:Medicinal_chemistry dbr:Sigma_receptor dbr:Valproic_acid dbr:Nicotinamide_phosphoribosyltransferase dbr:Extravasation_(intravenous) dbr:Immunosuppressive_drug dbr:File:TopoTarget_logo.jpg dbr:Topical_medication dbr:Pivotal_trial dbr:Onxeo dbr:Molecular_Pharmacology dbr:Portland_Press dbr:Ovarian_cancer dbr:Astellas dbr:Head_and_neck_cancers dbr:FasL dbr:Skin_diseases dbr:Malignancies dbr:Pro-apoptotic dbr:Recombinant_fusion_protein dbr:Colorectal_polyps dbr:Anti-cancer dbr:Preclinical dbr:Preclinical_stage dbr:T_cell_lymphoma dbr:Apoxis dbr:CuraGen_Corporation dbr:Division_of_Cancer_Treatment_and_Diagnosis dbr:Division_of_Carcinogenesis dbr:File:Hsp90.jpg dbr:Frankfurt_University_Hospital dbr:G2M_Cancer_Drugs_AG dbr:Nordic_Business_Report dbr:Oxford_University_Hospital dbr:Prolifix dbr:Prolifix_Ltd. |
| dbp:assets |
DKK 585.41 million , p. 24 (en) |
| dbp:equity |
DKK 411.79 million , p. 24 (en) |
| dbp:foundation |
2000 (xsd:integer) |
| dbp:homepage |
http://www.topotarget.com/ |
| dbp:industry |
dbr:Biotechnology |
| dbp:keyPeople |
(en) Anders Fink Vadsholt (en) Bo Jesper Hansen (en) Francois Martelet (en) Jean-Louis Misset (en) Peter Buhl Jensen (en) |
| dbp:location |
dbr:Denmark dbr:Copenhagen |
| dbp:logo |
200 (xsd:integer) |
| dbp:name |
TopoTarget (en) |
| dbp:netIncome |
DKK 140.46 million , p. 24 (en) |
| dbp:numEmployees |
53 (xsd:integer) |
| dbp:operatingIncome |
DKK 132.49 million , p. 24 (en) |
| dbp:revenue |
DKK 43.979 million , p. 24 (en) |
| dbp:type |
Public (en) |
| dbp:wikiPageUsesTemplate |
dbt:As_of dbt:Cite_journal dbt:Cite_web dbt:Decrease dbt:Increase dbt:Infobox_company dbt:Main dbt:Quote dbt:Reflist dbt:Use_dmy_dates dbt:OMX |
| dcterms:subject |
dbc:Cancer_research dbc:2014_disestablishments_in_Denmark dbc:Biotechnology_companies_disestablished_in_2014 dbc:Biotechnology_companies_established_in_2000 dbc:Biotechnology_companies_of_Denmark dbc:Companies_listed_on_Nasdaq_Copenhagen dbc:Danish_companies_established_in_2000 dbc:Defunct_companies_based_in_Copenhagen |
| gold:hypernym |
dbr:Company |
| rdf:type |
owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 yago:WikicatBiotechnologyCompaniesOfDenmark yago:WikicatCompaniesBasedInCopenhagen yago:WikicatCompaniesEstablishedIn2000 yago:WikicatCompaniesListedOnTheOMXExchanges yago:Abstraction100002137 yago:Company108058098 yago:Group100031264 yago:Institution108053576 yago:Organization108008335 yago:YagoLegalActor yago:YagoLegalActorGeo yago:YagoPermanentlyLocatedEntity dbo:Organisation yago:SocialGroup107950920 |
| rdfs:comment |
TopoTarget (Nasdaq Copenhagen: TOPO) was a Copenhagen-based biotechnology company focused on the discovery and development of drugs and therapies to treat cancer. In 2014, it merged with BioAlliance Pharma and is now part of . (en) |
| rdfs:label |
TopoTarget (en) |
| owl:sameAs |
freebase:TopoTarget yago-res:TopoTarget wikidata:TopoTarget https://global.dbpedia.org/id/2NiJq |
| prov:wasDerivedFrom |
wikipedia-en:TopoTarget?oldid=1094222004&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Hsp90.jpg wiki-commons:Special:FilePath/TopoTarget_logo.jpg |
| foaf:homepage |
http://www.topotarget.com/ |
| foaf:isPrimaryTopicOf |
wikipedia-en:TopoTarget |
| foaf:name |
TopoTarget (en) |
| is dbo:wikiPageRedirects of |
dbr:APO866 |
| is dbo:wikiPageWikiLink of |
dbr:Belinostat dbr:PEAC dbr:APO866 dbr:Nessa_Carey |
| is foaf:primaryTopic of |
wikipedia-en:TopoTarget |
